NCT05975593 MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
| NCT ID | NCT05975593 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Locally Advanced Cervical Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-01-11 |
| Primary Completion | 2032-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-01-11 with a primary completion date of 2032-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: * Confirmation of intent to receive radiotherapy for one of the following diagnoses: * Cervical cancer * Pancreatic cancer * ECOG performance status ≤ 2 * At least 18 years old * Able to understand and willing to sign an IRB-approved written informed consent document Exclusion Criteria: * Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician
Contact & Investigator
Cliff Robinson, M.D.
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT05975593 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Cervical Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05975593 currently recruiting?
Yes, NCT05975593 is actively recruiting participants. Contact the research team at clifford.robinson@wustl.edu for enrollment information.
Where is the NCT05975593 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT05975593 clinical trial?
NCT05975593 is sponsored by Washington University School of Medicine. The principal investigator is Cliff Robinson, M.D. at Washington University School of Medicine. The trial plans to enroll 60 participants.